Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 121, Issue 1, Pages 212-225Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI43144
Keywords
-
Categories
Funding
- Susan G Komen Breast Cancer Foundation [BCTR0601346]
- Avon Foundation [02 2008 081]
- Del Webb Foundation
- United States Department of Agriculture/Agricultural Research Service [6250 51000 055]
Ask authors/readers for more resources
Cancer cells have an efficient antioxidant system to counteract their increased generation of ROS However, whether this ability to survive high levels of ROS has an important role in the growth and metastasis of tumors' is not well understood Here, we demonstrate that the redox protein thioredoxin-like 2 (TXNL2) regulates the growth and metastasis of human breast cancer cells through a redox signaling mechanism TXNL2 was found to be overexpressed in human cancers, including breast cancers Knockdown of TXNL2 in human breast cancer cell lines increased ROS levels and reduced NF-kappa B activity, resulting m inhibition of in vitro proliferation, survival, and invasion In addition, TXNL2 knockdown inhibited tumorigenesis and metastasis of these cells upon transplantation into immunodeficient mice Furthermore, analysis of primary breast cancer samples demonstrated that enhanced TXNL2 expression correlated with metastasis to the lung and brain and with decreased overall patient survival Our studies provided insight into redox-based mechanisms underlying tumor growth and metastasis and suggest that TXNL2 could be a target for treatment of breast cancer
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available